Product capable of treating androgen alopecia and / or promoting hair growth and application of exosome

Abstract

The invention discloses a product capable of treating androgenetic alopecia and / or promoting hair growth and application of exosomes, the product comprises the product capable of treating androgenetic alopecia and / or promoting hair growth, and is characterized by comprising the exosomes obtained by stimulating mesenchymal stem cells through CHIR99021 and minoxidil combined with the exosomes. The disclosure verifies that the exosome obtained by stimulating mesenchymal stem cells through CHIR99021 can promote hair growth and treat androgenetic alopecia, and particularly, the hair growth effect is better when the exosome is combined with minoxidil, so that a product comprising the exosome and minoxidil can treat androgenetic alopecia and promote hair growth is provided.

Description

Technical Field

[0001] The present invention relates to the field of biopharmaceutical industry, and specifically to a product for treating androgenic alopecia and / or promoting hair growth and the application of exosomes. Background Art

[0002] Hair loss is categorized into scarring and non-scarring types, with androgenetic alopecia (AGA) being the most common type. Data from the National Health Commission indicates that the number of people experiencing hair loss in my country has exceeded 250 million, or one in every six people. Those under 30 years old account for 69.8% of the total, with the largest proportion occurring in the 26-30 age group, indicating a trend toward younger age groups experiencing hair loss.

[0003] Existing medications for treating hair loss are often slow to take effect, require continuous use, and can cause recurrence of hair loss after discontinuation. In severe cases, they can also cause various adverse reactions. Currently, multiple studies have shown that mesenchymal stem cells and exosomes can treat AGA and promote hair growth. For example, adipose-derived stem cell exosomes (ADSC-Exos) can regulate the hair follicle growth cycle and promote hair regeneration by promoting the proliferation and survival of hair follicles and dermal papilla cells (DPCs).

[0004] However, the hair growth effect of exosomes needs to be improved. Summary of the Invention

[0005] The present disclosure is made in view of the above-mentioned state of the prior art, and its purpose is to provide a product and application of exosomes that can treat androgenic alopecia and / or promote hair growth.

[0006] To this end, the first aspect of the present disclosure provides a product for treating androgenic alopecia and / or promoting hair growth, comprising exosomes obtained by stimulating mesenchymal stem cells with CHIR99021, and minoxidil used in combination with the exosomes. In the present disclosure, it was verified that exosomes obtained by stimulating mesenchymal stem cells with CHIR99021 can promote hair growth and treat androgenic alopecia. In particular, when the exosomes are used in combination with minoxidil, the hair growth effect is even better. Therefore, a product comprising the exosomes and minoxidil can be provided for treating androgenic alopecia and promoting hair growth.

[0007] In the product involved in the first aspect of the present disclosure, optionally, the exosomes and minoxidil are stored separately. Thus, a suitable storage method can be selected according to the properties of the exosomes and minoxidil for easy storage.

[0008] In the product involved in the first aspect of the present disclosure, optionally, the exosomes intervene in the host by being injected subcutaneously, and the minoxidil intervenes in the host by being applied externally.

[0009] In the product involved in the first aspect of the present disclosure, optionally, the mesenchymal stem cells are selected from any one of human umbilical cord mesenchymal stem cells, umbilical cord blood mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose mesenchymal stem cells, synovial mesenchymal stem cells, placental mesenchymal stem cells, liver mesenchymal stem cells, muscle mesenchymal stem cells, lung mesenchymal stem cells, pancreatic mesenchymal stem cells and dental pulp mesenchymal stem cells.

[0010] In the product involved in the first aspect of the present disclosure, optionally, the mesenchymal stem cells are selected from human umbilical cord mesenchymal stem cells.

[0011] In the product involved in the first aspect of the present disclosure, optionally, the product is a medicine or a cosmetic.

[0012] In the product involved in the first aspect of the present disclosure, optionally, the product further includes pharmaceutically acceptable excipients.

[0013] In the product involved in the first aspect of the present disclosure, optionally, the excipients include any one or more of a diluent, a filler, a binder, a disintegrant, a lubricant, a preservative, a sweetener, a colorant, a surfactant, a buffer, and an antioxidant.

[0014] A second aspect of the present disclosure relates to the use of exosomes in the preparation of products for treating androgenic alopecia and / or promoting hair growth. The exosomes are obtained by stimulating mesenchymal stem cells with CHIR99021. In the present disclosure, it is demonstrated that exosomes obtained by stimulating mesenchymal stem cells with CHIR99021 can promote hair growth and treat androgenic alopecia. Therefore, these exosomes can be used in the preparation of products for treating androgenic alopecia and / or promoting hair growth.

[0015] In the application involved in the second aspect of the present disclosure, optionally, the exosomes are used in combination with minoxidil, thereby helping to enhance its effect of promoting hair growth.

[0016] According to the present disclosure, a product for treating androgenic alopecia and / or promoting hair growth and the use of exosomes in preparing a product for treating androgenic alopecia and / or promoting hair growth can be provided. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 3 is a graph showing the GO analysis of exosome proteomics in the CHIR99021-treated group and the control group involved in the examples of the present disclosure.

[0018] Figure 2 1 is a flowchart showing the animal experiment involved in the examples of the present disclosure.

[0019] Figure 3 Schematic diagram showing the hair growth of each group of mice involved in the examples of the present disclosure.

[0020] Figure 4 Schematic diagram showing the hair length of each group of mice involved in the examples of the present disclosure.

[0021] Figure 5 2 is a schematic diagram showing the analysis results of the hair length of each group of mice involved in the examples of the present disclosure.

[0022] Figure 6 2 is a graph showing the HE staining results of mouse skin in each group involved in the examples of the present disclosure.

[0023] Figure 7A 1 is an immunofluorescence staining image of the hair follicles of three groups of mice involved in the examples of the present disclosure.

[0024] Figure 7B 1 is an immunofluorescence staining image of the hair follicles of another three groups of mice involved in the examples of the present disclosure. DETAILED DESCRIPTION

[0025] The preferred embodiments of the present disclosure are described in detail below with reference to the accompanying drawings. In the following description, identical components are assigned identical reference numerals, and duplicate descriptions are omitted. In addition, the accompanying drawings are merely schematic, and the proportions of the dimensions of the components and the shapes of the components may differ from the actual ones.

[0026] It should be noted that the terms "including" and "having" and any variations thereof in the present invention, such as a process, method, system, product or device that includes or has a series of steps or units are not necessarily limited to those steps or units clearly listed, but may include or have other steps or units that are not clearly listed or are inherent to these processes, methods, products or devices.

[0027] In addition, the subheadings and the like in the following description of the present invention are not intended to limit the content or scope of the present invention, but are merely provided as a guide for reading. Such subheadings should not be understood as dividing the content of the article, nor should the content under the subheadings be limited to the scope of the subheadings.

[0028] Abbreviations and their interpretations of proper nouns involved in this disclosure: The embodiments of the present invention are described in detail below. Examples of the embodiments are shown in the accompanying drawings, wherein the same or similar reference numerals throughout represent the same or similar elements or elements having the same or similar functions. The embodiments described below with reference to the accompanying drawings are exemplary and are intended only to explain the present invention and are not to be construed as limiting the present invention.

[0029] Those skilled in the art will understand that unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.

[0030] It should also be understood that terms, such as those defined in commonly used dictionaries, should be understood to have a meaning consistent with their meaning in the context of the prior art and will not be interpreted in an idealized or overly formal sense unless as defined herein.

[0031] Those skilled in the art will appreciate that, unless otherwise stated, the singular forms "a," "an," "said," and "the" used herein may also include plural forms. It should be further understood that the term "comprising" used in the specification of the present invention refers to the presence of the stated features, integers, steps, operations, elements, and / or components, but does not preclude the presence or addition of one or more other features, integers, steps, operations, elements, and / or groups thereof.

[0032] In the description of this specification, reference to the terms "one embodiment," "some embodiments," "examples," "specific examples," or "some examples" means that the specific features, structures, materials, or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. Moreover, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. In addition, those skilled in the art may combine and integrate different embodiments or examples described in this specification, as well as features of different embodiments or examples, unless otherwise inconsistent.

[0033] The first aspect of the present disclosure relates to a product that can treat androgenic alopecia and / or promote hair growth. The product may include exosomes obtained by stimulating mesenchymal stem cells with CHIR99021 (hereinafter referred to as chir-Exo). In the present disclosure, it is verified that exosomes obtained by stimulating mesenchymal stem cells with CHIR99021 can promote hair growth and treat androgenic alopecia. Therefore, a product comprising the exosomes is provided that can be used to treat androgenic alopecia and promote hair growth. In some examples, a product may include minoxidil. Minoxidil can be used in combination with exosomes. In other words, a product may include minoxidil combined with exosomes. In the present disclosure, it has been demonstrated that chir-Exo and minoxidil combine to achieve a more effective hair growth effect. Therefore, a product comprising these exosomes and minoxidil can be provided to treat androgenic alopecia and promote hair growth. In some examples, a product may include chir-Exo and minoxidil.

[0034] In some examples, chir-Exo can be stored separately from minoxidil, thereby enabling selection of an appropriate storage method based on the properties of the exosomes and minoxidil for easier storage.

[0035] In some examples, chir-Exo can be injected into the subcutaneous region to intervene in the host. In other words, chir-Exo can be administered by subcutaneous injection. In some examples, chir-Exo can be injected into the subcutaneous region at the site of hair loss to intervene in the host. In some examples, chir-Exo can be injected into the host at multiple subcutaneous points to intervene in the host. In some examples, chir-Exo can be added to a solvent for storage and / or use. In other words, the product can also include a solvent for chir-Exo. In some examples, the solvent for chir-Exo can be PBS. In some examples, the solvent for chir-Exo can also be other commonly used solvents that can carry exosomes.

[0036] In some examples, minoxidil is applied externally to the host. The use and dosage of minoxidil can be determined by reference to its instructions. For example, minoxidil can be applied to the hair removal area for intervention.

[0037] In some examples, the mesenchymal stem cells can be selected from any one of umbilical cord blood mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose mesenchymal stem cells, synovial mesenchymal stem cells, placental mesenchymal stem cells, liver mesenchymal stem cells, muscle mesenchymal stem cells, lung mesenchymal stem cells, pancreatic mesenchymal stem cells, and dental pulp mesenchymal stem cells.

[0038] In some examples, the mesenchymal stem cells can be preferably selected from human umbilical cord mesenchymal stem cells (hucMSCs). The mesenchymal stem cell-derived exosomes can be human umbilical cord mesenchymal stem cell-derived exosomes (huc-Exo). In this case, umbilical cord as a source of mesenchymal stem cells and their exosomes offers advantages over other sources such as bone marrow and liver, such as reduced risk to the human body and ease of collection. Umbilical cord-derived mesenchymal stem cells also possess enhanced proliferation and differentiation capabilities.

[0039] In some examples, human umbilical cord mesenchymal stem cells and their exosomes can be obtained from fresh umbilical cord tissue of newborns. In some examples, human umbilical cord mesenchymal stem cells can be cultured from umbilical cord tissue. In some examples, the human umbilical cord tissue can be cultured using a culture medium. In some examples, the culture medium can be α-MEM medium. In some examples, the culture medium can contain 10% fetal bovine serum, 100 U / mL (units per milliliter) penicillin, and 100 μg / mL (micrograms per milliliter) streptomycin. In this manner, human umbilical cord mesenchymal stem cells can be cultured.

[0040] In some examples, exosomes derived from human umbilical cord mesenchymal stem cells can be isolated after culturing human umbilical cord tissue in culture medium. In some examples, the culture supernatant can be filtered through a filter to obtain the exosomes. In some examples, the pore size (i.e., pore diameter) of the filter can be 0.22 μm. This removes larger particles from the supernatant while minimizing the retention of exosomes in the supernatant. In some examples, the filtered supernatant can be centrifuged, and the exosomes are the precipitate. In some examples, the filtered supernatant can be ultracentrifuged at 120,000 × g for 70 minutes, and the exosomes are the precipitate. In this manner, exosomes derived from human umbilical cord mesenchymal stem cells can be prepared.

[0041] In some examples, CHIR99021 can be a GSK-3α inhibitor and a GSK-3β inhibitor. In some examples, CHIR99021 can promote the secretion of exosomes from mesenchymal stem cells by increasing the intracellular content of MVBs and ILVs in mesenchymal stem cells and promoting MVB exocytosis. Thus, CHIR99021 can promote the increase in the intracellular content of MVBs and ILVs in mesenchymal stem cells and promote MVB exocytosis, thereby promoting the secretion of exosomes from mesenchymal stem cells. In some examples, the Wnt-βcatenin pathway is a signaling pathway. In mesenchymal stem cells, the Wnt-βcatenin pathway regulates processes such as cell proliferation, differentiation, and migration. In some examples, MVBs and ILVs are both intracellular vesicles that can participate in the transport and sorting of intracellular substances. In some examples, MVB exocytosis can release the contents of the MVBs outside the cell, forming exosomes.

[0042] In some cases, CHIR99021 can be added to the culture of mesenchymal stem cells. This yields exosomes from mesenchymal stem cells stimulated with CHIR99021. Compared to untreated exosomes, chir-Exo cells show a significant upregulation of proteins involved in telomere length maintenance. Therefore, chir-Exo cells may promote hair growth by regulating telomere length in hair follicle stem cells and delaying their aging.

[0043] In some examples, the product may be a medicine or a cosmetic. In some examples, the product may also include pharmaceutically acceptable excipients. In some examples, the excipients may include any one or more of a diluent, a filler, a binder, a disintegrant, a lubricant, a preservative, a sweetener, a colorant, a surfactant, a buffer, and an antioxidant. The excipients may also be other conventional medical excipients not described herein.

[0044] The second aspect of this disclosure relates to the use of exosomes in the preparation of products for treating androgenic alopecia and / or promoting hair growth. The exosomes are derived from mesenchymal stem cells stimulated with CHIR99021 (chir-Exo). This disclosure demonstrates that exosomes derived from mesenchymal stem cells stimulated with CHIR99021 can promote hair growth and treat androgenic alopecia. Therefore, these exosomes can be used in the preparation of products for treating androgenic alopecia and / or promoting hair growth.

[0045] In some cases, chir-Exo can be used in combination with minoxidil to enhance its hair growth promoting effects.

[0046] In some examples, the product may be a medicine or a cosmetic. In some examples, the product may also include pharmaceutically acceptable excipients. In some examples, the excipients may include any one or more of a diluent, a filler, a binder, a disintegrant, a lubricant, a preservative, a sweetener, a colorant, a surfactant, a buffer, and an antioxidant. The excipients may also be other conventional medical excipients not described herein.

[0047] To facilitate understanding of the present invention, the present invention is further explained below with reference to specific embodiments in conjunction with the accompanying drawings. However, the specific embodiments do not constitute a limitation on the embodiments of the present invention.

[0048] Experimental process In this embodiment, the test materials used are all conventional test materials in the field and can be purchased through commercial channels.

[0049] Experimental methods: 1. Cell Culture and Treatment Umbilical cord-derived mesenchymal stem cells were cultured in α-MEM medium containing 10% fetal bovine serum and 1% double-antibody. When the cell confluence reached 70% to 80%, the cells were cultured in serum-free medium for 48 hours, and the cell supernatant was collected. The cell supernatant was centrifuged at 10,000 × g for 1 hour, and the supernatant was taken to remove cell debris and larger vesicles. The supernatant was then centrifuged at 120,000 × g for 70 minutes to obtain exosomes. The exosomes were resuspended in PBS and stored for subsequent experiments.

[0050] Set up the following two experimental groups: CTRL group (control group): In the process of obtaining exosomes, when the cell confluence reached 70% to 80%, the cells were cultured in serum-free medium for 48 hours, and the cell supernatant was collected to obtain the exosomes of the CTRL group, that is, the exosomes without special treatment (huc-Exo).

[0051] CHIR99021-treated group: In the process of obtaining exosomes, when the cell confluence reached 70% to 80%, the cells were cultured with serum-free medium and CHIR99021 (concentration of 6.25 μmol / L) for 48 hours, and the cell supernatant was collected to obtain the exosomes (chir-Exo) of the CHIR99021-treated group. Figure 1 3 is a graph showing the GO analysis of exosome proteomics in the CHIR99021-treated group and the control group involved in the examples of the present disclosure.

[0052] 2. Establishment of Androgenic Alopecia (AGA) Model Six-week-old male C57BL / 6J mice weighing (20 ± 2) g were obtained from Jiangsu Huachuang Xinnuo Pharmaceutical Technology Co., Ltd. They were housed in a positive pressure, purified, ventilated animal room at 22–23°C, 20%–50% humidity, and artificial lighting to simulate daytime and nighttime fluctuations. Food and water were freely available.

[0053] An AGA model was established in C57BL / 6J mice using dorsal hair removal combined with intraperitoneal injection of dihydrotestosterone (DHT). Eighteen C57BL / 6J mice were selected and adaptively fed for one week, beginning the model intervention at 7 weeks of age. The AGA model group (15 mice) received intraperitoneal injections of DHT (1 mg / day / mouse, Solebol ID0310) on days -1, 5, and 13, respectively. The normal control group (3 mice) received intraperitoneal injections of sterile corn oil (1 mg / day / mouse, Beyotime ST2308) on days -1, 5, and 13. The dorsal hair of the mice was shaved with a depilatory cream one day after the first DHT / corn oil injection.

[0054] 3. Intervention measures Phase I study: Eighteen C57BL / 6J mice were randomly divided into six groups, with three mice in each group. ①Normal control group (NC group): normal C57BL / 6J mice + corn oil; ②DHT hair loss group (DHT group): AGA model mice were injected subcutaneously with 200 μl PBS at four points on the back of the hair loss area once every 7 days; ③DHT+minoxidil group (Mino group): AGA model mice plus minoxidil (5 mg / qod / mouse, Solebol IM0270) applied to the depilated area on the back every other day; ④DHT+untreated exosomes group (huc-Exo group): AGA model mice were subcutaneously injected with untreated exosomes (200 μg exosomes dissolved in 200 μl PBS) at four points on the back of the depilated area every 7 days; ⑤DHT+CHIR99021 pre-treated exosome group (chir-Exo group): AGA model mice were subcutaneously injected with chir-Exo (200 μg chir-Exo dissolved in 200 μl PBS) at 4 points on the back of the depilated area once every 7 days; ⑥DHT+CHIR99021 pre-treated exosomes+minoxidil group (Mino+chir-Exo group): AGA model group mice + chir-Exo (200 μg chir-Exo dissolved in 200 μl PBS) were subcutaneously injected at 4 points on the back hair removal area once every 7 days + minoxidil (5 mg / qod / mouse, Solebol IM0270) was applied to the back hair removal area every other day.

[0055] Figure 2 The figure shows the flow chart of the animal experiment involved in the example of the present disclosure. The hair growth of each group of mice was photographed on the 0th, 7th, 14th and 21st day with the same machine. The results are as follows: Figure 3 As shown, Figure 3 is a schematic diagram showing the hair growth of each group of mice involved in the examples of the present disclosure. Figure 3 The upper panel shows hair growth in mice during Trial Phase I, while the lower panel shows hair growth in mice during Trial Phase II. On day 21, 20 newly grown hairs were randomly collected from each mouse, and hair length was measured using Image J (an image processing software). Figure 4 Schematic diagram showing the hair length of each group of mice involved in the examples of the present disclosure. Figure 5 2 is a schematic diagram showing the analysis results of the hair length of each group of mice involved in the examples of the present disclosure.

[0056] Phase II study After collecting the newly grown hair, the mice were shaved on the back using a depilatory cream. The AGA model groups (i.e., DHT group, Mino group, huc-Exo group, chir-Exo group, and Mino+chir-Exo group) were injected intraperitoneally with DHT (1 mg / d / mouse) on days -1, 5, and 13, respectively. Minoxidil and exosomes were discontinued and the mice were observed for 21 days. The hair growth was photographed on days 4, 7, 14, and 21 using the same microscope. The results are shown in the figure below. Figure 3 On the 21st day, the mice were killed and skin tissue and blood samples were obtained.

[0057] Method 1: Histology and immunofluorescence staining (1) Mouse dorsal skin tissue was fixed in 4% paraformaldehyde for 72 hours. The 4% paraformaldehyde-fixed skin tissue samples were embedded in paraffin and sectioned at the maximum cross-section with a thickness of 5 μm. After dewaxing and hydration, the sections were stained with a hematoxylin-eosin (H&E) staining kit according to standard procedures. The sections were placed under a microscope to observe hair follicle data, and images were taken and statistically analyzed using Image J software. Figure 6 2 is a graph showing the HE staining results of mouse skin in each group involved in the examples of the present disclosure.

[0058] (2) For immunofluorescence staining, sections were dewaxed and hydrated, and then antigen retrieval was performed using a pH 9 antigen retrieval solution (servicebio, China) in a microwave oven. Sections were blocked in blocking goat serum for 1 hour, and then incubated overnight at 4°C with the addition of primary antibodies. The next day, sections were incubated with TRITC-labeled goat anti-rabbit IgG (Beyotime, China) and FITC-labeled goat anti-mouse IgG (Beyotime, China) at room temperature for 1 hour, followed by incubation with DAPI for 5 minutes, and finally mounted with anti-fluorescence quenching mounting medium. Images were captured using a fluorescence microscope and analyzed using Image J software. The primary antibodies used included CD34 (1:200, eBioscience 14–0341-82), Ki67 (1:100, Abclonal A20018), Sox9 (1:100, Abclonal A19710), and Tyrosine hydroxylase (1:200, Abclonal A12756). Figure 7A 1 is an immunofluorescence staining image of the hair follicles of three groups of mice involved in the examples of the present disclosure. Figure 7B 1 is an immunofluorescence staining image of the hair follicles of another three groups of mice involved in the examples of the present disclosure.

[0059] Statistical analysis All data are expressed as mean ± standard error. The differences between the two groups were analyzed by unpaired t-test or one-way analysis of variance, and then statistically tested by GraphPad Prism 10 software. The differences were considered statistically significant when P < 0.05.

[0060] Result Analysis 1. Figure 1 GO analysis showed that telomere length maintenance-related proteins (TERF2, NSMCE3, TEP1, DHX36, LRWD1, FKBP5, etc.) were significantly upregulated in chir-Exo, suggesting that it may promote hair growth by regulating the telomere length of hair follicle stem cells and delaying their aging.

[0061] 2. See Figure 3A phase I study found that at 14 days, the hair growth of mice treated with chir-Exo was significantly faster than that of the untreated exosome group (huc-Exo), and minoxidil could further enhance the hair growth-promoting effect of chir-Exo. At 21 days, the mice's hair was basically covered, with no significant differences between the groups. A phase II study found that at 7 days, both the chir-Exo group and the Mino+chir-Exo group showed more significant skin regeneration and hair island formation, while there was no significant difference between the Mino group and the DHT group. At 14 days, the chir-Exo group showed a significant increase in hair coverage, and Mino+chir-Exo further enhanced this effect. At 21 days, the hair growth of the chir-Exo group and the Mino+chir-Exo group was basically complete, followed by the huc-Exo group, and the DHT group and the Mino group had the lowest coverage.

[0062] 3. See Figure 4 and Figure 5 ,In terms of hair length, the minoxidil group (Mino) and the minoxidil combined with pre-treated exosomes group (Mino+chir-Exo) were significantly increased compared with the other groups.

[0063] 4. See Figure 6 The HE staining results of mouse skin showed that the miniaturization and reduction of hair follicles were significantly improved after chir-Exo treatment.

[0064] 5. See Figure 7A and Figure 7B The staining images of the mouse hair follicle area showed that the CD34-positive stem cell area was significantly expanded after chir-Exo treatment, suggesting that chir-Exo has an activation or proliferation-promoting effect on hair follicle stem cells.

[0065] These results indicate that chir-Exo can promote hair growth and treat androgenic alopecia, with significantly enhanced hair growth-promoting ability compared to huc-Exo. In particular, when chir-Exo is combined with minoxidil, the hair growth-promoting effect is even greater than when chir-Exo or minoxidil is used alone.

[0066] Thus, a product capable of treating androgenic alopecia and / or promoting hair growth, and a use of exosomes in preparing a product for treating androgenic alopecia and / or promoting hair growth can be provided.

[0067] Although the present disclosure has been described in detail above with reference to the accompanying drawings and embodiments, it will be understood that the above description does not limit the present disclosure in any form. Those skilled in the art may modify and change the present disclosure as needed without departing from the spirit and scope of the present disclosure, and such modifications and variations all fall within the scope of the present disclosure.

Claims

1. A product for treating androgenic alopecia and / or promoting hair growth, characterized in that: The invention comprises exosomes obtained by stimulating mesenchymal stem cells with CHIR99021, and minoxidil used in combination with the exosomes.

2. The product according to claim 1, characterized in that The exosomes and minoxidil are stored independently.

3. The product according to claim 1, characterized in that The exosomes intervene in the host by injecting into the subcutaneous tissue, and the minoxidil intervenes in the host by external application.

4. The product according to claim 1, characterized in that The mesenchymal stem cells are selected from any one of human umbilical cord mesenchymal stem cells, umbilical cord blood mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose mesenchymal stem cells, synovial mesenchymal stem cells, placental mesenchymal stem cells, liver mesenchymal stem cells, muscle mesenchymal stem cells, lung mesenchymal stem cells, pancreatic mesenchymal stem cells and dental pulp mesenchymal stem cells.

5. The product according to claim 1 or 4, characterized in that The mesenchymal stem cells are selected from human umbilical cord mesenchymal stem cells.

6. The product according to claim 1, characterized in that The product is a medicine or a cosmetic.

7. The product according to claim 1, characterized in that The product also includes pharmaceutically acceptable excipients.

8. The product according to claim 7, characterized in that The excipients include any one or more of diluents, fillers, binders, disintegrants, lubricants, preservatives, sweeteners, colorants, surfactants, buffers, and antioxidants.

9. Use of exosomes in preparing a product for treating androgenic alopecia and / or promoting hair growth, characterized in that: The exosomes are exosomes obtained by stimulating mesenchymal stem cells with CHIR99021.

10. The use according to claim 9, characterized in that The exosomes are used in combination with minoxidil.

Images